Lorigerlimab
Product Specifications
UNSPSC Description
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC)[1][2][3].
Target Antigen
CTLA-4; PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lorigerlimab.html
Solubility
10 mM in DMSO
Smiles
[Lorigerlimab]
References & Citations
[1]Jason J. Luke, et al. Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort. Journal of Clinical Oncology 2023 41:6_suppl, 155-155. |[2]Berezhnoy A, et al. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163. |[3]Trojaniello C, Luke JJ, Ascierto PA. Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Front Oncol. 2021 Jun 10;11:670726.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99714/Lorigerlimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99714/
Clinical Information
Phase 2
CAS Number
2416595-46-3
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
